Oppenheimer & Co’s Akero Therapeutics AKRO Stock Holding History

Oppenheimer & Co’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,330	Closed	-$297K	–	1605
2025 Q1	$297K	Buy	+7,330	New	+$311K	﹤0.01%	1283

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co's AKRO Position: Q2 2025 in Review

Oppenheimer & Co sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 7,330 shares — an estimated $297K sold.

Oppenheimer & Co first reported a position in AKRO in Q1 2025 and held it in 1 quarter. The position peaked at $297K in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

Oppenheimer & Co reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
Oppenheimer & Co sold 7,330 Akero Therapeutics shares in Q2 2025, an estimated $297K.
Oppenheimer & Co first reported a position in Akero Therapeutics in Q1 2025 and held it in 1 quarter.
Oppenheimer & Co's Akero Therapeutics position peaked at $297K in Q1 2025.
257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Oppenheimer & Co's 13F filing for Q2 2025, filed 31 Jul 2025.